123 related articles for article (PubMed ID: 37455424)
1. Group sequential multi-arm multi-stage survival trial design with treatment selection.
Wu J; Li Y
J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
[TBL] [Abstract][Full Text] [Related]
2. Group sequential multi-arm multi-stage trial design with treatment selection.
Wu J; Li Y; Zhu L
Stat Med; 2023 May; 42(10):1480-1491. PubMed ID: 36808736
[TBL] [Abstract][Full Text] [Related]
3. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
[TBL] [Abstract][Full Text] [Related]
4. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
[TBL] [Abstract][Full Text] [Related]
5. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
Trials; 2011 Mar; 12():81. PubMed ID: 21418571
[TBL] [Abstract][Full Text] [Related]
6. Design and monitoring of multi-arm multi-stage clinical trials.
Ghosh P; Liu L; Senchaudhuri P; Gao P; Mehta C
Biometrics; 2017 Dec; 73(4):1289-1299. PubMed ID: 28346823
[TBL] [Abstract][Full Text] [Related]
7. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
8. An optimised multi-arm multi-stage clinical trial design for unknown variance.
Grayling MJ; Wason JMS; Mander AP
Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
[TBL] [Abstract][Full Text] [Related]
9. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
Jaki T; Hampson LV
Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
[TBL] [Abstract][Full Text] [Related]
10. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
Blenkinsop A; Parmar MK; Choodari-Oskooei B
Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Lin J; Bunn V
Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
[TBL] [Abstract][Full Text] [Related]
12. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
13. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
Trials; 2013 Jan; 14():23. PubMed ID: 23343147
[TBL] [Abstract][Full Text] [Related]
14. Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.
Chen LM; Ibrahim JG; Chu H
J Biopharm Stat; 2014; 24(4):817-33. PubMed ID: 24697500
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
16. Optimal design of multi-arm multi-stage trials.
Wason JM; Jaki T
Stat Med; 2012 Dec; 31(30):4269-79. PubMed ID: 22826199
[TBL] [Abstract][Full Text] [Related]
17. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
Shan G
J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
[TBL] [Abstract][Full Text] [Related]
18. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
19. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
20. Choice of futility boundaries for group sequential designs with two endpoints.
Schüler S; Kieser M; Rauch G
BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
